Systemic Therapies for Acne

  • Marisa Kardos GarshickEmail author
  • Alexa Kimball
  • Lynn Drake


Individuals with moderate-to-severe inflammatory acne may warrant systemic therapies, especially if they are unresponsive to topical treatments, or have significant quality of life decrements, which is not uncommon in this population. Specific clinical features, including the type and severity of acne, the presence of scarring, and the association with abnormal menses, can help guide the appropriate course of treatment. All dosages mentioned in this section must be adjusted according to the individual patient.


Sebaceous Gland Idiopathic Intracranial Hypertension Diffuse Idiopathic Skeletal Hyperostosis Ethinyl Estradiol Cyproterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27:33–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1–37.PubMedCrossRefGoogle Scholar
  3. 3.
    Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3):S200–10.PubMedCrossRefGoogle Scholar
  4. 4.
    Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat. 2006;17:217–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30:215–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Antonio JR, Pegas JR, Cestari T, Do Nascimento LV. Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety. J Dermatolog Treat. 2008; 19:210–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79:9–25.PubMedGoogle Scholar
  9. 9.
    Eady EA, Cove JH, Holland KT, Cunliffe WJ. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol. 1990;122:233–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol. 1993; 128:556–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Coch Data Syst Rev. 2003; Issue 1: CD002086.Google Scholar
  12. 12.
    McManus P, Iheanacho I. Don’t use minocycline as first line oral antibiotic in acne. BMJ. 2007;334:154.PubMedCrossRefGoogle Scholar
  13. 13.
    Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Stewart DM, Torok HM, Weiss JS, et al. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006;78:11–20.PubMedGoogle Scholar
  15. 15.
    Fleischer Jr AB, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline for acne vulgaris. Cutis. 2006;78:21–31.PubMedGoogle Scholar
  16. 16.
    Sturkenboom MC, Meier CR, Jick H, Striker BH. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med. 1999;159:493–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ. Antibiotics, acne, and staphylococcus aureus colonization. Arch Dermatol. 2011;147:917–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis. 2007;79(6):430–4.PubMedGoogle Scholar
  19. 19.
    Amnesteem® (Isotretinoin Capsules USP) [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc. 2010.Google Scholar
  20. 20.
    Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10:490–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45(5):S150–7.PubMedCrossRefGoogle Scholar
  22. 22.
    White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998;134:376–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol. 2007;157(6):1240–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med. 1985;313:981–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985; 313:837–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol. 1993; 7:175–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Margolis DJ, Attie M, Leyden JJ. Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin therapy for acne vulgaris. Arch Dermatol. 1996;132:769–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Reddy D, Siegel CA, Sands BE, et al. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006;101:1569–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry. 2008;69:526–32.PubMedCrossRefGoogle Scholar
  30. 30.
    Crockett SD, Gulati A, Sandler RS, et al. A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol. 2009;104: 2387–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol. 2008;144: 1197–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007;26:210–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Chia CY, Lane W, Chibnall J, et al. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol. 2005;141:557–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am. 2009; 93:1161–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Kelekci KH, Kelekci S, Incki K, et al. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. Int J Dermatol. 2010; 49:775–9.PubMedGoogle Scholar
  36. 36.
    Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726–35.PubMedCrossRefGoogle Scholar
  37. 37.
    Junkins-Hopkins JM. Hormone therapy for acne. J Am Acad Dermatol. 2010;62(3):486–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Coch Data Syst Rev. 2009; Issue 3: CD004425.Google Scholar
  39. 39.
    Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123–30.PubMedGoogle Scholar
  40. 40.
    Yaz® (Drospirenone/Ethinyl estradiol) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.: 2011.Google Scholar
  41. 41.
    Castelli WP. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Am J Obstet Gynecol. 1999;180:S349–56.PubMedCrossRefGoogle Scholar
  42. 42.
    Helms SE, Bredle DL, Zajic J, Jatjoura D, Brodell RT, Krishnarao I. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36:705–10.PubMedCrossRefGoogle Scholar
  43. 43.
    Dickinson BD, Altman RD, Nielsen NH, Sterling ML, Council on Scientific Affairs, American Medical Association. Interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001;98:853–60.PubMedCrossRefGoogle Scholar
  44. 44.
    Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills. Am J Obstet Gynecol. 2008;199:351.e1–e12.CrossRefGoogle Scholar
  45. 45.
    Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–14.PubMedCrossRefGoogle Scholar
  46. 46.
    Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Coch Data Syst Rev. 2009; Issue 2:CD000194.Google Scholar
  47. 47.
    Saint-Jean M, Ballanger F, Nguyen J, Khammari A, Dréno B. Importance of spironolactone in the treatment of acne in adult women. J Eur Acad Dermatol Venereol. 2010;25:1480–1. doi: 10.1111/j.1468-3083.2010.03926.x.PubMedCrossRefGoogle Scholar
  48. 48.
    Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112:124–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498–502.PubMedCrossRefGoogle Scholar
  51. 51.
    Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol. 2010;28:17–23.PubMedCrossRefGoogle Scholar
  52. 52.
    Van Wayjen R, van den Ende A. Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic, and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103:241–51.PubMedCrossRefGoogle Scholar
  53. 53.
    Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419–28.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Marisa Kardos Garshick
    • 1
    Email author
  • Alexa Kimball
    • 1
  • Lynn Drake
    • 1
  1. 1.Department of DermatologyMassachusetts General HospitalBostonUSA

Personalised recommendations